Raji CD19 Antigen Panel Cell Lines

Tested for Mycoplasma, bacterial and fungal content, post-freeze viability, and short terminal repeat (STR) analysis for cell line identification.

Established in 1963 from Burkitt′s lymphoma in an 11 year old male. Growth is in the form of single cells without attachment and as macroscopically visible clumps containing many hundreds of cells. Resistant to VSV. This cell line carries the latent Epstein-Barr Virus (EBV) genome and is positive for EBNA. Raji is sometimes referred to as a ′non-producer′; the EBV genome carries deletions attributed to preventing the formation of virus particles. Ethnicity: Black

The Raji CD19 antigen panel cell lines feature CD19 expressed at varying levels (KO, low, and high). These cell lines enable researchers to screen and evaluate the binding and potency of CD19-targeted immunotherapies in a biologically-relevant cellular research model.

This product is a panel of three (3) genetically modified cell lines involving the CD19 gene. The panel consists of a CD19 knockout cell line (CD19^-/-) as well as a CD19^low and a CD19^high expression cell line. The CD19^-/- cell line was generated using CompoZr^® Zinc Finger Nuclease technology, and the two CD19 expression cell lines were generated using MISSION^® lentivirus. The CD19^low and CD19^high cell lines express CD19 at low and high levels relative to the CD19^-/- cell line (CD19^high > CD19^low > CD19^-/-) as measured via fluorescence-activated cell sorting (FACS). As a comparison, wild type Raji cells demonstrate CD19^medium expression as measured via FACS.

The STR profile of these cell lines match that of its parental cell line - ECACC catalog number 85011429.

CompoZr is a registered trademark of Merck KGaA, Darmstadt, Germany

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

ATG001A-1VL: Raji CD19 Knockout
ATG001B-1VL: Raji CD19 Low
ATG001C-1VL: Raji CD19 High